EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieBeobachtungsstudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study)

Katsuyoshi Matsuoka, Fumihito Hirai, Kenji Watanabe, Ryota Hokari, Taku Kobayashi, Masayuki Saruta, Hiroshi Nakase, Takahiro Suzuki, Gakuto Yamazaki, Toshifumi Hibi, Mamoru Watanabe, Tadakazu Hisamatsu

Journal of Gastroenterology · 2025-12 · 60 (12) · 1523-1534

DOI: 10.1007/s00535-025-02299-9 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Gastroenterology, online erschienen am 22.09.2025. Verfasst von Katsuyoshi Matsuoka und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Sakura Medical Center, 564-1, Shimoshizu, Sakura-Shi, C…. Hauptthemen laut MEDLINE: Colitis, Ulcerative. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kissei Pharmaceutical Co., Ltd., EA Pharma Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Carotegrast methyl is approved for treating patients with moderately active ulcerative colitis with inadequate response to 5-aminosalicylic acid agents. However, real-world evidence to guide optimal use is limited. This retrospective study aimed to characterise suitable patient profiles, identify biomarkers predictive of carotegrast methyl efficacy, and determine the appropriate timing for treatment evaluation.

Methods

We analysed data from 186 patients enrolled in a phase 3 trial of carotegrast methyl (96 carotegrast methyl, 90 placebo). We assessed biomarkers (leucine-rich α -2 glycoprotein, C-reactive protein, faecal calprotectin, and anti-integrin αvβ6 antibody titres) alongside clinical outcomes and assessed symptom diaries and maintenance therapies.

Results

Low disease activity at baseline (partial Mayo score ≤ 5) was associated with higher remission rates (56.1 vs. 33.3%). Anti-integrin αvβ6 antibody titres of < 44.6 U/mL at baseline predicted higher clinical remission rates (49.1 vs. 26.8%). Symptom improvement was detectable from week 2. Faecal calprotectin correlated with the endoscopic subscore at the end of treatment ( ρ = 0.566); a faecal calprotectin level of < 387.5 µg/g predicted Mayo endoscopic subscore 0/1. Most patients maintained remission with oral 5-aminosalicylic acid alone; the 1-year maintenance rate was 56.5%.

Conclusions

Carotegrast methyl appears most effective in patients with moderately active ulcerative colitis with low disease activity, with week 2 and beyond as an appropriate time point for assessing efficacy. Anti-integrin αvβ6 antibody titre shows promise in predicting response to carotegrast methyl. Faecal calprotectin may serve as a non-invasive surrogate for evaluating endoscopic healing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeAdultAgedFemaleHumansMaleMiddle AgedBiomarkersC-Reactive ProteinFecesIntegrinsLeukocyte L1 Antigen ComplexMesalamineRemission InductionRetrospective StudiesSeverity of Illness IndexTime FactorsTreatment Outcome

Stichwörter der Autor:innen

Anti-integrin αvβ6CalprotectinCarotegrast methylLeucine-rich α-2 glycoproteinUlcerative colitis

Substanzen

BiomarkersC-Reactive ProteinIntegrinsLeukocyte L1 Antigen ComplexMesalamine

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Sakura Medical Center, 564-1, Shimoshizu, Sakura-Shi, Chiba, 285-8741, Japan. matsuoka@fk2.so-net.ne.jp.
  • Department of Gastroenterology and Medicine, Fukuoka University Hospital, Fukuoka, Japan.
  • Department of Internal Medicine for Inflammatory Bowel Disease, University of Toyama, Toyama, Japan.
  • Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan.
  • Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.

Förderung

  • Kissei Pharmaceutical Co., Ltd.
  • EA Pharma Co., Ltd.

Zitieren

APA

Matsuoka, K., Hirai, F., Watanabe, K., Hokari, R., Kobayashi, T., Saruta, M., Nakase, H., Suzuki, T., Yamazaki, G., Hibi, T., Watanabe, M., & Hisamatsu, T. (2025). Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study). Journal of Gastroenterology, 60(12), 1523-1534. https://doi.org/10.1007/s00535-025-02299-9

Vancouver

Matsuoka K, Hirai F, Watanabe K, Hokari R, Kobayashi T, Saruta M, et al. Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study). Journal of Gastroenterology. 2025;60(12):1523-1534. doi:10.1007/s00535-025-02299-9

BibTeX
@article{Matsuoka2025,
  author = {Matsuoka, Katsuyoshi and Hirai, Fumihito and Watanabe, Kenji and Hokari, Ryota and Kobayashi, Taku and Saruta, Masayuki and Nakase, Hiroshi and Suzuki, Takahiro and Yamazaki, Gakuto and Hibi, Toshifumi and Watanabe, Mamoru and Hisamatsu, Tadakazu},
  title = {Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study)},
  journal = {Journal of Gastroenterology},
  year = {2025},
  volume = {60},
  number = {12},
  pages = {1523--1534},
  doi = {10.1007/s00535-025-02299-9}
}
Kostenlos starten →